Development of novel RAS inhibitory agents for cancer therapy
开发用于癌症治疗的新型 RAS 抑制剂
基本信息
- 批准号:9379114
- 负责人:
- 金额:$ 6.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-12-01 至 2018-11-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAllelesAmino AcidsAntibodiesBiochemistryBiologyCellsClinicalCysteineDataDevelopmentDirected Molecular EvolutionEnvironmentFrequenciesFutureHumanIn VitroIndividualLaboratoriesLeadLigandsMalignant NeoplasmsMalignant neoplasm of pancreasMethodsMissionModalityMolecular ConformationMutateMutationNIH 3T3 CellsOncogenesOncogenicOncoproteinsOxidation-ReductionPatientsPeptide HydrolasesPeptidesPhenotypePhosphoric Monoester HydrolasesPoint MutationProtein EngineeringProtein IsoformsProteinsRas InhibitorReagentResearchRewardsRiskRoleSchemeSignal TransductionSpecificityTechnologyTertiary Protein StructureTestingTherapeuticTherapeutic AgentsTransformed Cell LineTreatment EfficacyTumor Cell LineTumorigenicityVirus-like particleWorkanticancer researchcancer therapycross reactivityefficacy testingin vivoindividual patientinhibitor/antagonistmutantnanocapsulenanoparticleneoplastic cellnovelnovel strategiesnovel therapeuticsprogramspublic health relevanceras Oncogeneras Proteinssuccesstooltumortumorigenesistumorigenic
项目摘要
DESCRIPTION (provided by applicant): Despite a great deal of progress in our understanding of the biochemistry of Ras and its role in tumorigenesis, development of effective therapeutic inhibitors of Ras to date has been disappointing. Given the frequency of Ras mutations in human cancers, there is a critical need to develop targeted inhibitors of this oncoprotein for treatment of patients with Ras-positive tumors. Our proposal represents a novel approach to this challenge. We will develop high affinity reagents that specifically target the four most frequent mutant KRas alleles in human tumors. Aim 1 will utilize the monobody platform as a method to isolate highly specific affinity reagents that target the following KRas mutant proteins: G12D, G12V, G12C, and G13D. The specificity and potency of these reagents will be determined in vitro. Aim 2 will then determine the specificity and selectivity of these KRas mutation specific monobodies at abrogating the tumorigenic phenotype of KRas-driven tumors vs tumors driven by other oncogenes. These studies represent a novel approach toward developing highly specific Ras inhibitory reagents and thus have the potential to make a major impact on cancer therapy. In addition, this project is highly relevant to the NCI's mission of targeting Ras-dependent cancers as evidence by the recent Ras Initiative at the Frederick National Laboratory for Cancer Research.
描述(由申请人提供):尽管我们在理解Ras的生物化学及其在肿瘤发生中的作用方面取得了很大进展,但迄今为止Ras的有效治疗性抑制剂的开发一直令人失望。鉴于Ras突变在人类癌症中的频率,迫切需要开发这种癌蛋白的靶向抑制剂,用于治疗Ras阳性肿瘤患者。我们的建议代表了应对这一挑战的新方法。我们将开发高亲和力试剂,专门针对人类肿瘤中四种最常见的突变KRas等位基因。目的1将利用单体平台作为分离靶向以下KRas突变蛋白的高度特异性亲和试剂的方法:G12D、G12V、G12C和G13D。将在体外测定这些试剂的特异性和效价。然后,目标2将确定这些KRas突变特异性单体在消除KRas驱动的肿瘤与由其他癌基因驱动的肿瘤的致瘤表型方面的特异性和选择性。这些研究代表了开发高度特异性Ras抑制剂的新方法,因此有可能对癌症治疗产生重大影响。此外,这个项目是高度相关的NCI的使命的目标Ras依赖性癌症的证据,最近的Ras倡议在弗雷德里克国家癌症研究实验室。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John P O'Bryan其他文献
John P O'Bryan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John P O'Bryan', 18)}}的其他基金
Development of novel Ras inhibitory agents for cancer therapy"
用于癌症治疗的新型Ras抑制剂的开发"
- 批准号:
9213585 - 财政年份:2015
- 资助金额:
$ 6.63万 - 项目类别:
Development of novel RAS inhibitory agents for cancer therapy
开发用于癌症治疗的新型 RAS 抑制剂
- 批准号:
9188050 - 财政年份:2015
- 资助金额:
$ 6.63万 - 项目类别:
Regulation Of Ischemic Preconditioning By Compartmentalized Signal Transduction
通过区室化信号转导调节缺血预处理
- 批准号:
8110093 - 财政年份:2009
- 资助金额:
$ 6.63万 - 项目类别:
Regulation Of Ischemic Preconditioning By Compartmentalized Signal Transduction
通过区室化信号转导调节缺血预处理
- 批准号:
7737536 - 财政年份:2009
- 资助金额:
$ 6.63万 - 项目类别:
Regulation Of Ischemic Preconditioning By Compartmentalized Signal Transduction
通过区室化信号转导调节缺血预处理
- 批准号:
8266384 - 财政年份:2009
- 资助金额:
$ 6.63万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 6.63万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 6.63万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 6.63万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 6.63万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 6.63万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 6.63万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 6.63万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 6.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 6.63万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 6.63万 - 项目类别: